Table 1.
Sample size and event rate according to ancestry and cohort.
| Ancestry | Cohort | Total (N) | Event (N) | Event Rate (%) |
|---|---|---|---|---|
|
| ||||
| European/European American | ARIC | 2,184 | 543 | 24.9 |
| BIOME | 851 | 160 | 18.8 | |
| CHS | 379 | 225 | 59.4 | |
| FHS | 547 | 185 | 33.8 | |
| MESA | 392 | 64 | 16.3 | |
| MGB | 1,161 | 389 | 33.5 | |
| PMBB | 603 | 244 | 40.5 | |
| PROSPER | 452 | 39 | 8.6 | |
| REGARDS | 303 | 195 | 64.4 | |
| ROTTERDAM | 611 | 98 | 16 | |
| SANFORD | 2,062 | 174 | 8.4 | |
| UKBB | 15,643 | 1,499 | 9.6 | |
| WGHS | 2,043 | 105 | 5.1 | |
| WHI | 3,887 | 998 | 25.7 | |
|
| ||||
| Subtotal | 31,118 (63.2%) | 4,918 (54.9%) | 15.8 | |
|
| ||||
| African American | ARIC | 1,142 | 310 | 27.1 |
| BIOME | 1,764 | 467 | 26.5 | |
| CHS | 130 | 76 | 58.5 | |
| JHS | 726 | 92 | 12.7 | |
| MESA | 508 | 85 | 16.7 | |
| PMBB | 1,242 | 388 | 31.2 | |
| REGARDS | 2,483 | 733 | 29.5 | |
| WHI | 3,129 | 693 | 22.1 | |
|
| ||||
| Subtotal | 11,124 (22.6%) | 2,844 (31.8%) | 25.6 | |
|
| ||||
| Hispanic/Latino | BIOME | 2,681 | 668 | 24.9 |
| MESA | 482 | 89 | 18.5 | |
| WHI | 1,162 | 177 | 15.2 | |
|
| ||||
| Subtotal | 4,325 (8.8%) | 934 (10.4%) | 21.6 | |
|
| ||||
| East Asian | KOGES | 2,317 | 185 | 8.0 |
| MESA | 194 | 42 | 21.6 | |
| WHI | 152 | 33 | 21.7 | |
|
| ||||
| Subtotal | 2,663 (5.4%) | 260 (2.9%) | 9.8 | |
|
| ||||
| Total | 49,230 | 8,956 | 18.2 | |
A total of 49,230 participants with T2D from 16 cohorts and of multiple ancestries were included in this study: 31,118 (63.2%) of European, 11,124 (22.6%) of African American, 4,325 (8.8%) of Hispanic/Latino, and 2,663 (5.4%) of East Asian ancestry. The total incident CVD event rate was 18.2% with those of African ancestry having the highest event rate of 25.6%. ARIC, Atherosclerosis Risk in Communities Study; BIOME, BioMe BioBank; CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; JHS, Jackson Heart Study; KOGES, Korean Genome and Epidemiology Study; MESA, Multi-Ethnic Study of Atherosclerosis; MGB, Mass General Brigham Biobank; PMBB, Penn Medicine BioBank; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; REGARDS, Reasons for Geographic and Racial Differences in Stroke Study; ROTTERDAM, Rotterdam Study; SANFORD, Sanford Health; UKBB, UK Biobank; WGHS, Women's Genome Health Study; and WHI, Women's Health Initiative.